Overview
Belgium medical device maker's Q1 revenue rose yr/yr and beat analyst expectations
Q1 gross margin fell to 57% from 62% due to production yield issues now addressed
Company expects Q2 U.S. revenue to grow 25-30% sequentially, full-year revenue €36-40 mln
Outlook
Company expects Q2 2026 U.S. net revenue to grow 25-30% sequentially
Nyxoah sees 2026 worldwide net revenue between €36 mln and €40 mln
Company expects 2026 gross margin of 60-62% and operating expenses of €97-99 mln
Result Drivers
U.S. COMMERCIAL EXPANSION - Sequential revenue growth driven by strong activity at existing sites and high growth in new site openings, per CEO Olivier Taelman
REIMBURSEMENT CLARITY - Company cited consistent reimbursement landscape and 100% approval rate on closed U.S. prior authorization submissions as supporting results
PRODUCTION YIELD ISSUES - Gross margin fell to 57% from 62% due to production yield issues, which the company says have been addressed
Company press release: ID:nGNE6TdMB2
Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
Beat
EUR 6.4 mln
EUR 6.02 mln (6 Analysts)
Q1 Gross Margin
57.00%
Q1 Gross Profit
EUR 3.64 mln
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Nyxoah SA is €9.00, about 235.2% above its May 12 closing price of €2.69
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)